VEGFA and hepatocellular carcinoma: This importance of angiogenesis in HCC is also reflected by the fact that most approved treatments for advanced HCC patients, including sorafenib, target several angiogenic pathways, including the pro-angiogenic VEGF/VEGF receptor (VEGFR) pathway [40,93].